NPPC and glaucoma: Current investigational therapies for glaucoma predominantly focus on IOP-lowering mechanisms, including Rho-kinase inhibitors [35], nitric oxide (NO) donors [36], adenosine receptor modulators [37], small-interfering RNAs (siRNAs) [38], C-type natriuretic peptides (CNP) [39], and LIM domain kinase inhibitors [40].